SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is being linked by traders to founder Patrick Soon-Shiongs scheduled oncology fireside chat, where he is expected to discuss trial progress, as well as anticipation around bladder-cancer regulatory milestones. Speculation about a partnership, a connection to the NIH cancer-vaccine initiative, and a possible short squeeze is circulating, but those claims are unconfirmed.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflakes Agentic Marketplace Discovery launch and a bullish analyst price-target update are driving attention, alongside a broader rotation into AI-related software. Traders are highlighting the rally and potential breakout, while skeptics question the stocks valuation and profitability.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs sovereign-AI and customized-software opportunities, coincided with a breakout to fresh highs. Bulls celebrate the momentum and speculate about a short squeeze, while skeptics warn that the valuation is stretched and the rally could reverse.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after a sharp rally and breakout to fresh highs alongside strength in software stocks, with traders pointing to momentum and continued interest in cloud and AI-related software. Bulls see room for the move to continue, while bears cite the stocks rich valuation and warn of a pullback.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys partnership with Metas Muse to enable AI-agent purchases through Shop Pay is fueling interest, with bulls seeing a new commerce channel and skeptics questioning how quickly it can be monetized. Traders are also debating whether the sharp rally can continue amid volatility and resistance near recent highs.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Repeated analyst price-target cuts and valuation concerns are dominating discussion around APPs sharp pullback ahead of its upcoming earnings report. Long-term bulls point to the companys ad growth, cash flow and e-commerce opportunity, while many holders are frustrated by the volatile price action and debate whether the selloff reflects deteriorating prospects or an opportunity.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas proposed non-binding deal for its first U.S. data center and broader AI-infrastructure expansion plan are driving discussion. Some traders welcome the U.S. growth opportunity, while many question how the capital-intensive plans will be financed and want proof of execution, raising concerns about dilution and whether the deal will close.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile ambitions have triggered a sharp selloff in T-Mobile shares as traders weigh the prospect of a new wireless competitor. The community is split between viewing the threat as a long-term risk to carriers and calling the reaction an overreaction given SpaceXs need to build out its network.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A reported NIH-backed push to accelerate personalized cancer vaccines is drawing attention to Mercks role in the field, including its V940 partnership with Moderna and promising melanoma-trial results. Traders see the initiative as supportive of Mercks oncology prospects, though some caution that a research push does not guarantee near-term revenue.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

Michael Burrys disclosed QXO stake has sparked renewed attention after a prolonged share-price decline, with traders debating whether the prominent investors position could prompt short covering. Some see it as a vote of confidence in QXOs building-products roll-up, while others question whether the attention changes the companys underlying outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push

A reported NIH-backed effort to accelerate personalized cancer vaccines is lifting vaccine-related biotech shares, with traders linking BioNTechs oncology pipeline to the broader theme. Some are optimistic about the sector tailwind but question why BNTX is lagging Modernas stronger move.

BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push 

Equity

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.


Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?

Moderna (NASDAQ: MRNA) has delivered the pivotal cancer result investors were waiting for, while BioNTech Se (NASDAQ: BNTX) offers greater financial flexibility and a broader oncology pipeline. The question is whether Moderna's stronger clinical proof deserves its valuation premi...

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers   New York, NY – September 15, 2026 – Market News Updates News Commentary – The antiviral market is entering a period where the need for new treatments is becoming impossible […]
The post A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat appeared first on Financial News Media.

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?

PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.

MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?

Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.

BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down

BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.

BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’

BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients. 


Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer Inc. (NYSE: PFE, Pfizer) and BioNTech SE (Nasdaq: BNTX, BioNTech) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY XFG...

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology   New York, NY – August 26, 2026 – Market News Updates News Commentary – If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of […]
The post A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity appeared first on Financial News Media.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$96.96
Prev Close	$92.06
Open	$92.45
Dividend Yield	0.00%
50-Day Moving Average	$98.90
Beta	0.86
Avg. Volume	866,760.43
PE Ratio	-12.36

52-Week High	$124.00
52-Week Low	$79.52
Market Capitalization	$24.36B
EPS (Annual)	-$5.30
Price to Book	1.20
Revenue Per Employee	$414,872.02

Feed

News

Sentiment

Earnings

Fundamentals

Info

BNTX Fundamentals